Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

FATE THERAPEUTICS INC (FATE)

$2.41 -4.37% NASDAQ: FATE · 15-min delayed
  • SAN DIEGO, California
  • Public · NASDAQ: FATE
  • 161 employees
$230.8MMarket cap
$6.6MRevenue · FY2025
-$136.3MNet income
161Employees
FATENASDAQ
2013IPO

About FATE THERAPEUTICS INC

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$6.6M
Net income
-$136.3M
Total assets
$318.9M
Market cap
$230.8M
Operating margin
-2222.4%
Net margin
-2051.1%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$6.6M
Operating expenses
$154.3M
Operating income
-$147.7M
Income tax
$2.0K
Net income
-$136.3M
EPS (basic)
$-1.15
EPS (diluted)
$-1.15

Balance sheet

Total assets
$318.9M
Current assets
$208.7M
Total liabilities
$111.8M
Current liabilities
$36.1M
Shareholders’ equity
$207.2M

Cash flow

Operating cash flow
-$106.1M
Investing cash flow
$111.2M
Financing cash flow
$5.5M
Net cash flow
$10.6M

Statements via Polygon.io (SEC filings)

NASDAQ: FATE
$2.41 -4.37%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.92 $3.11

52-week range

Market cap
$230.8M
EPS (diluted)
$-1.15
Shares outstanding
95.8M
Open
Day range
Prev close
Volume
IPO date
Oct 1, 2013

Fate Therapeutics Inc (FATE) Stock Price

  • Reported a net loss of $136.3M in FY2025.
  • Revenue declined 88% from FY2021 to FY2025.
  • Trading 23% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review FATE THERAPEUTICS INC.

Write a review
Newsroom

News about FATE THERAPEUTICS INC

News & sentiment via Polygon.io

FAQ

Fate Therapeutics Inc: frequently asked questions

Is Fate Therapeutics Inc an American company?

Fate Therapeutics Inc is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Fate Therapeutics Inc headquartered?

Fate Therapeutics Inc is headquartered in San Diego, California, United States.

Is Fate Therapeutics Inc publicly traded?

Yes — Fate Therapeutics Inc is a publicly traded company. Its stock trades under the ticker symbol FATE on the NASDAQ.

What does Fate Therapeutics Inc do?

Fate Therapeutics Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →